if you look at the drivers of big Pharma acquisitions they’re usually based on the target having a compelling pipeline (eg suite of antibody drug conjugates in oncology) or a standout groundbreaking drug like the Crown Jewels
——Dmx fits neither of those.
——/Beyond this trial the larder looks bare, and the dimx drug itself performing better than a placebo when other drugs in this space outperform it, well I can’t see Big Pharma boardrooms getting excited.
if you look at the drivers of big Pharma acquisitions they’re...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $186.8M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.5¢ | 33.5¢ | $1.194M | 3.480M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 181739 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 395705 | 4 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.0¢ |
Change
-0.005 ( 1.45 %) |
||||
| Open | High | Low | Volume | ||
| 35.0¢ | 35.5¢ | 33.5¢ | 1411237 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| DXB (ASX) Chart |